Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, David Steensma, MD, of the Dana-Farber Cancer Institute, Boston, MA, highlights the unmet needs in low-risk myelodysplastic syndromes (MDS) currently. Dr Steensma discusses relapse following hypomethylating agent treatment, transfusion-dependence and iron overload, and those with low neutrophil and platelet counts.